Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 25,000 shares at $42.04 ($1.0M) on 2015-04-16, disclosed to the SEC on 2015-04-20.
Scheduled sale ($1.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.59 | 24,800 | $1.0M | 99.2% |
| 2 | $42.04 | 200 | $8K | 0.8% |
| Total | $41.59 avg | 25,000 | $1.0M | 100% |
| Filing → |
| [AAVL] | SELL | 2015-06-08 | $200K | — | Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-18 | $798K | — | Filing → |